Review assesses evidence linking GLP-1 receptor agonists to serious adverse events

A narrative review in the Journal of Internal Medicine appraises evidence on seven potentially serious adverse events linked to glucagon-like peptide-1 (GLP-1) receptor agonists. These treatments offer benefits for weight reduction, glycaemic control in type 2 diabetes, and cardiovascular and renal outcomes. The review considers mechanistic studies, spontaneous reports, randomized trials and cohort studies; the available abstract provides no pooled sample size or numerical risk estimates.

Gallbladder and biliary disease has the most consistent evidence supporting a causal association. Diabetic retinopathy complications appear most consistent with early worsening following rapid glycaemic improvement in patients with pre-existing retinopathy. Causality remains uncertain for thyroid cancer, non-arteritic anterior ischaemic optic neuropathy, suicidal behaviour and self-harm, acute pancreatitis, and intestinal obstruction.

The authors note that rare events, incomplete ascertainment in trials and residual confounding in observational studies limit inference. Even substantial relative risk increases generally translate into small absolute increases in broad populations, although risks may become clinically important in patients with high baseline risk. Treatment decisions should weigh the strength and uncertainty of safety evidence against individual baseline risk, expected benefits, available alternatives and patient preferences. This account is based on the abstract; the full review was not available for assessment.